Reviewer’s report

Title: Comparison of the safety of pegaptanib sodium in the treatment of age-related macular degeneration in subjects with or without diabetes mellitus: A retrospective, pooled data analysis

Version: 2 Date: 22 February 2012

Reviewer: Matthias Maier

Reviewer’s report:

Dear authors,

your manuscript “Comparison of the safety of pegaptanib sodium in the treatment of age-related macular degeneration in subjects with or without diabetes mellitus: A retrospective, pooled data analysis” is well written and easy to understand. The topic is interesting and the discussion is well balanced and supported by the data.

Your presentation shows interesting pooled data and references are adequate.

On page 3 line 3 and 4 need to be corrected: The Off-label intravitreal use (with the exception of ranibizumab, which was approved in Europe since 11 January 2011).....

Although all authors are company employees, after a minor revision the paper can be accepted.

Best regards,

Your Reviewer

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: Yes, but I do not feel adequately qualified to assess the statistics.